We provide updated results (11 October 2023 through 29 February 2024) from our previously conducted test-negative case-control study in Kaiser Permanente Southern California to evaluate sublineage-specific effectiveness of the BNT162b2 XBB1.5-adapted vaccine. Results suggest that XBB1.5-adapted vaccines may have reduced effectiveness against JN.1 versus XBB sublineages.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11250225 | PMC |
| http://dx.doi.org/10.1093/ofid/ofae370 | DOI Listing |
Publication Analysis
Top Keywords
effectiveness bnt162b2
8
bnt162b2 xbb
4
xbb vaccine
4
vaccine xbb
4
xbb jn1
4
jn1 sublineages
4
sublineages provide
4
provide updated
4
updated october
4
october 2023
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!